The activation of AMPK combined with anti-PD-1 and anti-CTLA4 antibodies or with a HMGCR inhibitor exhibited synergic anti-cancer activity in murine tumor models, supporting their potential clinical use. This evidence concerns the gene PDCD1 and cancer.